![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
Department of Pediatrics,1 Department of Pathology,2 Institute for Cancer Genetics,3 Department of Neurology, College of Physicians and Surgeons of Columbia University, New York, New York,6 Department of Biochemistry, Fukui Medical University, Fukui Japan,4 Lombardi Cancer Center, Department of Oncology, Georgetown University, Washington, DC5
Received 30 August 2004/ Returned for modification 9 November 2004/ Accepted 18 January 2005
 |
ABSTRACT |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
INTRODUCTION |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Expression of Id proteins can be reactivated in human cancer, and it has been proposed that deregulated Id signaling may promote multiple attributes of malignancy (27). Two Id family members, Id1 and Id3, are expressed in tumor blood vessels, where they render endothelial cells competent for the "angiogenic switch" (32, 33, 50). Another member of the Id family, Id2, binds and opposes the function of the Rb tumor suppressor protein (17, 25, 53). Previous mouse genetics experiments demonstrated that Id2 is essential for the death and phenotypic abnormalities of Rb-null embryos (18, 26). These studies established that Rb must restrain Id2 activity during development to prevent ectopic proliferation and apoptosis and to promote differentiation. However, Id2 is also a direct transcriptional target of Myc oncoproteins, and its expression is elevated in human neuroectodermal tumors carrying activated myc oncogenes (13, 24, 39, 57).
Disruption of Rb function is found in most human malignancies, and mice with a single Rb allele are predisposed to pituitary tumorigenesis in the intermediate lobe (15, 20, 29). The mouse pituitary intermediate lobe is a small organ that reaches full maturity in mid- to- late gestation (51). The cells of origin of pituitary tumors in Rb+/– mice are proliferating melanotroph progenitors, and the initiating event is loss of heterozygosity (LOH) at the residual Rb allele (38). LOH requires mitotic activity and is highly inefficient in fully differentiated cells (1, 7, 43). Interestingly, recent data suggest that Id proteins provide an indispensable signal for suppression of differentiation and efficient self-renewal of progenitor cells (63).
Although the role of Id2 as a target of Rb during development of the nervous system and hematopoiesis has been established, it remains unclear whether regulation of Id2 activity is part of the tumor suppressor function of Rb. To elucidate the mechanism that governs the proliferative state of Rb+/– melanotropes and Rb-null pituitary tumor cells, we analyzed the role of Id2 during pituitary carcinogenesis. Here, we report that Id2 is required at multiple stages of pituitary tumorigenesis initiated by loss of Rb. Id2 controls the timing of differentiation and exit from cell cycle of proliferating Rb+/– melanotropes, thus dictating the efficiency of tumor initiation. It also mediates the deregulated cell cycle progression and growth of pituitary tumor cells lacking Rb. Finally, we present data showing that Id2 is necessary and sufficient for expression of vascular endothelial growth factor (VEGF), thus contributing to the angiogenic switch of Rb-null pituitary tumors. This function of Id2 is recapitulated in human neuroblastoma cells, providing an explanation for the accumulation of Id2 in the most aggressive forms of this embryonal tumor.
|
MATERIALS AND METHODS |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Histopathology and immunohistochemistry. Pituitary glands were excised from mice, fixed in 10% neutral formalin, and embedded in paraffin, and 5-µm sections in the horizontal plane were serially cut. Embryos were harvested from timely pregnant mice at E15.5, fixed overnight in 10% formalin, and processed as above. Sagittal sections were prepared for evaluation of the pituitary intermediate lobe. For analysis of early focal tumor lesions, sections of the whole pituitary from Rb+/– and Id2–/–; Rb+/– 3-month-old mice were stained with hematoxylin and eosin (H&E) and the number of foci was scored in each section using a magnification of x60 to x100. The number of cells in each independent early tumor focus was determined by counting the number of tumor cells in each focus in the sections in which the tumor focus was present. Statistical significance was determined by using an unpaired t test. The proliferation index in tumor lesions was calculated by counting the percentage of bromodeoxyuridine (BrdU)-positive nuclei in individual tumor lesions, using nine serial sections from each 3-month-old and 4-month-old Rb+/– and Id2–/–; Rb+/– mouse, respectively. The proliferation and mitotic indices in the embryonic pituitary intermediate lobe were calculated by counting the percentage of BrdU-positive nuclei out of the total number of nuclei in the pituitary intermediate lobe by using four serial sections from each pituitary. Significance was tested using an unpaired t test. Antibodies used in immunohistochemical analysis were Id2 (C-20) from Santa Cruz Biotechnology, MASH-1 from Pharmingen, proopiomelanocortin (POMC) from Cortex Biochem, p27Kip1 from Transduction Laboratories, BrdU from Chemicon, VEGF AF-493-NA from R&D systems, thrombospondin-1 (TSP-1) from Neomarkers, PECAM from BD Pharmingen, and hypoxia-inducible factor 1 alpha subunit from Novus Biological. Immunostaining was performed on formalin-fixed, paraffin-embedded serial sections by standard procedures. Avidin-biotin peroxidase complex techniques were used for primary antibody detection (Vectastain kit; Vector Laboratories). Staining was developed using diaminobenzidine (brown precipitate). Slides were counterstained with hematoxylin. Controls included no primary antibody and/or normal rabbit or mouse serum and tissues from Id2-null mice.
Vascular analysis of pituitary tumors. Tumor-bearing animals were anesthetized and then immediately infused with 5.0 ml of a curable orange latex injection compound, Microfil MV-122 (Microfil). The compound was allowed to cure at 4°C overnight before the tumors were harvested. The tissue was cleared in increasing concentrations of glycerol, as specified in the manufacturer's protocol. The vascular architecture was visualized with an SZX12 Olympus microscope.
Cell culture. Neuroblastoma cells were cultured in Dulbecco modified Eagle medium with 10% fetal bovine serum. REF-52 cells were infected with an adenovirus vector expressing Id2 or Ad-green fluorescent protein vector at a multiplicity of infection (MOI) of 100. Cells were harvested at the indicated times and processed for Northern blot and Western blot analyses. To generate SH-N and IMR32 cells expressing ectopic Id2, cells were transfected with pCMV-Id2 and pCMV-Flag-Id2 or the corresponding empty vectors and selected with G418. For differentiation experiments, LAN-1 cells were exposed to 2 µM retinoic acid (Sigma).
siRNA. LAN-1 cells were transfected with pSuper.retro vectors (OligoEngine) by using Lipofectamine 2000 (Invitrogen). The expression vectors encode a small interfering RNA siRNA expression cassette including the H1 promoter of RNA polymerase III. The targeted Id2 sequences were CATGAACGACTGCTACTCC in pSuper.Retro112 and GGTGAGCAAGATGGAAAT in pSuper.Retro171. After transfection, cells were selected in puromycin (2 µg/ml) for 48 h and subsequently subjected to Western blot analysis or plated for clonogenic assay.
Western blot analysis Cell lysates were prepared in RIPA buffer containing protease and phosphatase inhibitors, and proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes, and finally visualized by enhanced chemiluminescence (Amersham-Pharmacia). The antibodies used in this study have been described previously (24, 26).
Northern blot analysis. Total RNA was isolated using the Trizol reagent (Invitrogen). Then, 20 µg of total RNA from each sample was separated by electrophoresis and transferred to a Nitran Plus membrane (Schleicher & Schuell). Membranes were stained with methylene blue for evaluation of RNA loading and probed with the coding portion of the mouse or human VEGF gene.
|
RESULTS |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
-melanocyte-stimulating hormone (-MSH) by Rb-null tumor cells, were remarkably delayed in Id2-null mice. However, the latency between early clinical symptoms and death was shorter than that in Rb+/– mice. Regardless of the Rb status, the Id2 mutant mice are smaller than their littermates from the neonatal period and exhibit symptoms of intestinal dysfunction (48, 64). The suboptimal physical conditions of Id2-null mice may reduce their tolerance to the increased intracranial pressure associated with pituitary tumors. Thus, the observed difference in survival between Rb+/– and Id2–/–; Rb+/– mice may underestimate the contribution of Id2 to the development of pituitary cancer. We reasoned that if loss of Id2 delays tumorigenesis in Rb+/– mice, pituitary tumors should develop later and/or display slower growth in the absence of Id2. We sacrificed Rb+/– mice with different Id2 backgrounds on postnatal day 200 (P200) and performed gross examination of the pituitary gland. As shown in Fig. 1B, 100% of Rb+/– mice (nine of nine) but only 14% of Id2–/–; Rb+/– animals (one of seven) had grossly enlarged, irregular glands suggestive of established tumors (P = 0.0002, Fisher's exact P value). Three (30%) of ten Id2+/–; Rb+/– mice had normal pituitaries. Histologic analysis from age-matched animals showed extensive tumor growth with entirely subverted pituitary glands in the Rb+/– genotype. Conversely, Id2–/–; Rb+/– pituitaries contained considerably fewer tumor cells, clustered in individual foci, and still had recognizable intermediate lobes (Fig. 1C). These findings are consistent with delayed development and/or slower progression of tumors in the compound mutant animals. Loss of Id2 induces premature differentiation and cell cycle arrest of Rb+/– melanotropes. The intermediate lobe of the pituitary gland can be first identified in the mouse on embryonic day 14 (E14), a time when melanotrope precursors undergo active proliferation (38). The proliferation of melanotropes decreases significantly after birth and ceases almost completely after postnatal day 35 (P35). Since cell proliferation is required for stochastic loss of the residual Rb allele, the initiating event in melanotroph carcinogenesis that leads to Rb LOH has been traced to embryonic and early postnatal life (38). To ask whether Id2 is required for progression of the cell cycle in the intermediate lobe of the pituitary gland during this time window, we labeled E15.5 Rb+/– and Id2–/–; Rb+/– embryos with BrdU and performed immunostaining for BrdU (Fig. 2A). Quantitation of the proliferative index in the developing intermediate lobe determined by BrdU staining demonstrated that 14.6% of nuclei in Id2–/–; Rb+/– pituitaries (n = 5) were labeled, compared with 22.2% of nuclei for Rb+/– controls (n = 4, P = 0.005; unpaired t test), (Fig. 2B). The mitotic index confirmed this finding (Rb+/–, 2.6 ± 0.6%; Id2–/–; Rb+/–, 1.3 ± 0.1%; P = 0.008). Interestingly, Id2 was highly expressed in proliferating melanotropes at E15.5 but its expression was extinguished in the postmitotic cells of the adult pituitary (Fig. 2C; also see Fig. 4A).
|
|
-MSH (51). Neurogenic bHLH proteins are essential activators of POMC promoter expression (44, 45). The bHLH factor MASH1 is expressed in mature melanotropes with a pattern fully corresponding to that of POMC expressing cells (31). As described for the neurogenic bHLH transcription factors in the nervous system, MASH1 is probably a component of the hierarchy of multiple bHLH factors involved in determination and differentiation of the melanotroph lineage in the pituitary gland (47). Because the best-characterized biochemical function of Id2 is the inhibition of bHLH-mediated transcription, we hypothesized that reduced proliferation of Id2-null melanotropes might be associated with premature differentiation. MASH1 expression was barely detectable in Rb+/– melanotropes on E15.5 but was markedly increased in the intermediate lobe of Id2–/–; Rb+/– pituitaries (Fig. 2D). Expression of POMC was correspondingly elevated in Id2-null melanotropes (Fig. 2E). Differentiation induced by neurogenic bHLH transcription factors is associated with increased expression of the cdk inibitor p27Kip1 (10). Expression of p27Kip1 followed the same pattern as that of MASH1 and POMC, with significantly higher levels in the absence of Id2 (Fig. 2F). At the level of sensitivity of the immunohistochemical analysis, we failed to detect significant differences in the expression of MASH1, POMC, and p27Kip1 between Rb+/+ and Rb+/– melanotropes (data not shown). These results indicate that loss of Id2 in the intermediate lobe of the mouse pituitary relieves bHLH proteins from an inhibitory control and induces premature activation of the bHLH transcription cascade. The outcome is premature exit from the cell cycle and differentiation of Rb+/– melanotropes at a time when cell cycle progression is essential for LOH at the residual Rb allele and tumor initiation. Loss of Id2 decreases number and size of early focal lesions and impairs proliferation of pituitary tumor cells in Rb+/– mice. Following Rb LOH, the earliest morphologically distinct pituitary tumor cells are detected as microscopic foci of atypical cells (early atypical proliferates [EAPs]) (38, 56). Each EAP is thought to originate from a single genetic event, and by P90 all Rb+/– mice have multiple tumor foci that later expand, fuse, and replace most of the intermediate lobe. To determine the role of Id2 in the early events of pituitary tumorigenesis, we analyzed pituitary glands from Rb+/– and Id2–/–; Rb+/– 90-day-old mice (Table 1; Fig. 3). To assess accurately the number and size of individual EAPs, we performed serial sectioning of the entire glands, stained sections with H&E, and analyzed each section to determine the number of foci and the total number of tumor cells within each focus. In the absence of Id2, the number of tumor foci was reduced by 50% (P = 0.003) (Table 1; Fig. 3A). Furthermore, the average number of tumor cells contained in each Id2–/–; Rb+/– focus was approximately half of that found in the Rb+/– focus (P = 0.011) (Table 1; Fig. 3B). Remarkably, loss of Id2 led to a fourfold reduction of the total number of tumor cells per pituitary (P = 0.0006) (Table 1). To determine the mechanism of compromised growth in Id2-deficient tumor cells, we examined cell proliferation and apoptosis in 3- and 4-month-old Rb+/– and Id2–/–; Rb+/– pituitary tumors, respectively. In the absence of Id2, BrdU labeling was significantly reduced in the pituitary tumor foci (Fig. 3C). Quantitation of the proliferation index in four pairs of Id2–/–; Rb+/– and Rb+/– pituitaries demonstrated that 6.0 and 16.6% of nuclei stained positive for BrdU in Id2–/–; Rb+/– and Rb+/– controls, respectively (P = 0.027) (Fig. 3D). However, the analysis of apoptosis by TUNEL assays and examination of hematoxylin-and-eosin stained sections revealed low levels of cell death with no differences between the two genotypes (data not shown). These findings suggest that impaired proliferation and premature differentiation of Id2-null melanotropes decrease the probability of the initiating Rb LOH event, thus leading to the reduced number of early tumor foci observed in Id2–/–; Rb+/– pituitaries. They also indicate that, at an early stage of tumor progression, Id2 contributes to an increase in the cell number and size of early tumor lesions because it provides Rb-null tumor cells with a proliferative advantage without an obvious effect on apoptosis.
|
|
Id2 mediates pituitary tumor angiogenesis. One of the most important attributes of tumor progression is the ability to develop new blood vessels (5). There is wide acceptance of the notion that, beyond a critical size, the "angiogenic switch" is required for growth of the tumor mass. The intermediate lobe of the pituitary gland is poorly vascularized (41). However, Rb-null tumors undergoing rapid expansion became highly angiogenic (Fig. 1B). We determined the extent of tumor vascularization by perfusing Rb+/– and Id2–/–; Rb+/– animals carrying advanced tumors with curable orange latex. The large tumors arising in Rb+/– pituitaries were highly vascularized, with large vessels and extensive capillary networks. In contrast, the small tumors that arose in Id2–/–; Rb+/– mice contained very few vessels and occasionally exhibited gross hemorrhage and necrosis (Fig. 5A). When pituitary tumors were stained for PECAM, an endothelial cell marker, the number of positive vascular structures was visibly higher in Rb+/– than Id2–/–; Rb+/– mice (Fig. 5B). Impaired angiogenesis in Id2-null pituitary tumors may be caused by higher expression of antiangiogenic molecules and/or decreased ability to upregulate proangiogenic factors. A recent study reported that the antiangiogenic protein thrombospondin-1 (TSP-1) is a target of transcriptional repression by Id1 and that its expression is increased in Id1-null mice (59). However, TSP-1 immunostaining was not elevated in Id2-null pituitary tumors (Fig. 5C), thus making TSP-1 upregulation an unlikely mechanism for the angiogenic defect of Id2–/–; Rb+/– tumors.
|
, the key factor promoting expression of VEGF in hypoxic cells, was undetectable in those lesions (Fig. 5F). The strikingly different ability of Rb+/– and Id2–/–; Rb+/– tumors to initiate expression of VEGF at an early, avascular stage of tumor progression, combined with the absence of VEGF even in advanced Id2-null tumors, suggests that Id2 is essential for production of VEGF during pituitary tumorigenesis. Deregulated Id2 is sufficient and necessary for cellular proliferation and expression of VEGF. To address whether Id2 could induce the expression of VEGF, we first infected REF52 fibroblasts with an adenovirus vector expressing Id2 and green fluorescent protein in cis from an internal ribosomal entry site (Ad-Id2). Infection with Ad-Id2 markedly enhanced the expression of VEGF, which paralleled the time course of ectopic Id2 (Fig. 6A). Conversely, infection with Ad-GFP control virus did not change VEGF.
|
Although Id2 is abundant in N-myc-amplified neuroblastoma, it has not been clear whether deregulated Id2 mediates a specific tumorigenic function(s) of human neuroblastoma cells. Treatment of N-myc-amplified neuroblastoma cells with retinoic acid induces cell cycle arrest and differentiation, and downregulation of N-myc precedes the phenotypic response (52). Recent data suggested that expression of VEGF is modified during cellular differentiation (9, 58). Given the regulatory role of N-Myc and Id2 in multiple differentiation pathways, we asked whether Id2 controls the expression of VEGF in a cellular model of neuronal differentiation. In the N-myc-amplified neuroblastoma cell line LAN-1, addition of retinoic acid led to a rapid (within 1 day) and sustained (up to 5 days) decrease in the levels of N-Myc, Id2 and VEGF (Fig. 6E). Exit from the cell cycle occurred only after 2 days of treatment with retinoic acid, as indicated by inhibition of cyclin A and accumulation of p27Kip1. These results suggest that inhibition of the expression of VEGF is not consequent to cell cycle arrest and may require early downregulation of Id2. To investigate the effect of Id2 on the retinoic acid-mediated decrease of VEGF, we infected LAN-1 with the Id2 adenovirus. Indeed, transduction of LAN-1 with Ad-Id2 prevented down-regulation of VEGF by retinoic acid (Fig. 6F). As a further test of the role of Id2 in cell proliferation and accumulation of VEGF by N-myc-amplified neuroblastoma, we targeted the expression of endogenous Id2 in LAN-1 with the vector pSuper.retro, which directs the synthesis of siRNAs matching two independent sequences from the Id2 mRNA (pRSId2-112 and pRSId2-171). Transfection of pRSId2-112 and pRSId2-171 resulted in efficient suppression of Id2 expression. Western blot analysis revealed that loss of Id2 was associated with powerful inhibition of VEGF expression. Suppression of Id2 and VEGF took place in the absence of changes of Id1, suggesting that the decreased expression of VEGF was a specific consequence of suppression of Id2 (Fig. 6G). Silencing of Id2 also resulted in almost complete cessation of cell proliferation as shown by the greatly reduced clonogenic ability of LAN-1 cells transfected with each of the two Id2-siRNA plasmids (Fig. 6H). In transient promoter-luciferase reporter assays, Id2 did not activate a –2362/+956 human VEGF promoter/regulatory region, suggesting that Id2 regulates VEGF expression in an indirect fashion (data not shown). Together, these results indicate that Id2 is sufficient to induce VEGF in fibroblasts and neuroblastoma cell lines. They also suggest that accumulation of Id2 in N-myc-amplified neuroblastoma tumor cells is necessary for proliferation and constitutive expression of VEGF.
|
DISCUSSION |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Id2 in pituitary tumor initiation. We have shown that Id2 is expressed abundantly in the developing and proliferating intermediate lobe of the mouse pituitary gland but absent in the adult and quiescent organ. Within the time window of Rb LOH, Id2-null melanotropes display early withdrawal from the cell cycle with accumulation of the cdk inhibitor p27Kip1 and premature expression of differentiation markers of the melanotroph lineage. These effects appear to be initiated by loss of the negative control imposed by Id2 on bHLH transcription factors expressed in the intermediate lobe of the developing pituitary gland. Consequently, Id2-null pituitary cells in the intermediate lobe undergo premature activation of the bHLH transcription cascade, with early differentiation and exit from the cell cycle. Indeed, neurogenic bHLH proteins bind and activate transcription from specific E-boxes in the POMC regulatory sequence and promote the differentiation of POMC-expressing cells (44, 45). Together, these findings identify Id2 as a factor that sets the timing of differentiation and quiescence of cells of the melanotroph lineage. Recently, it was shown that the most critical barrier to malignant transformation mediated by inactivation of the pocket proteins (Rb, p107, and p130) is terminal differentiation rather than apoptosis (8, 55). By showing that expression of Id2 prevents premature differentiation and sustains malignant transformation of Rb+/– melanotroph precursors, our results provide a molecular explanation to this observation.
In the absence of Id2, premature cell cycle exit and differentiation of developing melanotropes narrow the time window for tumor-initiating events, thus providing resistance to malignant transformation. The observation that Id2–/–; Rb+/– pituitaries contain markedly fewer early tumor lesions suggests that the proportion of individual melanotropes undergoing LOH at the residual wild-type Rb allele is lower in Id2-null pituitaries. The notion that efficiency of Rb inactivation in the pituitary determines the latency of tumor development is supported by the accelerated tumorigenesis found in chimeric mice and conditional Rb mutants (34, 60, 61). In these mouse models, melanotropes with complete inactivation of Rb are already present during early pituitary development and a second genetic event is not required for malignant transformation. Recent results have suggested that Rb deficiency leads to higher rates of genomic instability, a phenomenon implicated in both the origin and progression of most malignant tumors (30, 36, 65). It is tempting to speculate that deregulated Id2 activity resulting from loss of Rb may be one of the effecting mechanisms leading to the increased rate of chromosomal alterations.
Id2 in proliferation of Rb mutant cells. After completing differentiation, mature and quiescent melanotropes in the adult intermediate lobe extinguish the expression of Id2. However, Id2 is the only Id protein expressed by Rb-null pituitary tumor cells, suggesting that either maintenance or reactivation of Id2-dependent signaling is selected for tumor progression in the absence of Rb. The mechanism by which mouse and human Rb-null tumors accumulate high levels of Id2 is unknown, but we suggest that it may be related to loss of the repressor function of Rb on the genomic promoter of c-myc, whose protein product acts as a transcriptional activator for Id2 (16, 26).
The early lesion analysis has demonstrated that Id2-null EAPs are significantly smaller, have a lower proliferation index, and contain half the number of tumor cells than those identified in mice with intact Id2. This suggests that Id2 is also necessary for aberrant proliferation of pituitary tumor cells after the Rb LOH. Thus, the phenotypic consequences of loss of Id2 can be explained by impaired cell cycle progression in the intermediate lobe before and after the Rb LOH initiating event. In support of this notion, the aberrant expression of the G1-S cyclins E and A observed in Rb-null pituitary tumors is reversed in the absence of Id2. However, accumulation of cyclin D1 in Id2-null pituitary tumors may be the event that partially compensates for Id2 deficiency to ensure residual proliferation. This observation is in agreement with earlier studies showing that Id2 and cyclin D1 implement parallel and alternative pathways to enhance cell proliferation (25, 35). These data help to define a broad scope of effects of deregulated Id2 activity in the absence of Rb that extends to aberrant expression of cyclins and uncontrolled progression of the cell cycle.
Id2 in tumor angiogenesis.
For continued growth and survival, a tumor must promote angiogenesis. Our study directly links angiogenesis with Id2. Through gain- and loss-of-function experiments with the Rb+/– pituitary tumor model and human neuroblastoma cells, we have shown that Id2 is essential for the angiogenic switch during tumor progression. This conclusion is supported by (i) the impaired vascularization and defective production of VEGF of Id2-null pituitary tumors in the Rb mutant background; (ii) the impaired expression of HIF-1 by Id2-null pituitary tumors; (iii) the enhanced production of VEGF by normal and tumor cells expressing ectopic Id2; (iv) the coregulation of Id2 and VEGF in the differentiation response of neuroblastoma tumor cells to retinoic acid and the rescue of VEGF inhibition by expression of Id2; and (v) the reduced synthesis of VEGF in the neuroblastoma cell line LAN-1 in which endogenous Id2 has been suppressed by siRNA.
Several studies have implicated an indispensable role of VEGF in tumor angiogenesis, particularly in tumors of embryonal origin (2, 9, 23, 58). Other studies have reported that multiple oncogenic events combined with inactivation of tumor suppressor genes upregulate the expression of VEGF either directly or through constitutive activation of growth factor-mediated signaling (3, 6, 28, 54, 66). Our data are consistent with a model whereby loss of Rb results in activation of Id2 signaling, which in turn upregulates VEGF. The nonredundant role played by Id2 to promote the expression of VEGF in vivo and in vitro reproduces a similar activity recently attributed to Myc, an oncogenic transcription factor that induces both VEGF and Id2 gene expression, suggesting that Id2 may participate in the proangiogenic functions of Myc. Our data do not exclude the possibility that, as shown for Myc, Id2 promotes angiogenesis by inducing multiple positive cytokines. We also found that, like Myc, Id2 failed to induce luciferase activity driven by the VEGF promoter/enhancer (4). Thus, the mechanism by which the Myc-Id2 pathway activates expression of VEGF remains to be elucidated (4, 11, 14, 26, 37, 42).
The Id2 requirement for proper expression of VEGF and possibly other angiogenic cytokines has profound implications. Loss of the Id family members Id1 and Id3 leads to defective tumor vascularity because of cell-autonomous effects in endothelial cells, which are unable to respond to VEGF (32, 33). We propose a model whereby cooperation between Id proteins supports tumor growth and angiogenesis. Deregulated Id2 activity inactivates the Rb tumor suppressor pathway in tumor cells and promotes the expression of VEGF. Expression of Id1 and Id3 in the tumor endothelium renders the target cells competent for VEGF signaling. Together, these results suggest that the dual accumulation of Id proteins observed in tumor and endothelial cells from the most aggressive neuroectodermal neoplasms may be indispensable for tumor angiogenesis (57).
|
ACKNOWLEDGMENTS |
|---|
This work was supported by grants from NIH-NCI to A.L. (R01-CA101644) and A.I. (R01-CA85628).
|
FOOTNOTES |
|---|
|
REFERENCES |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
2. Backman, U., A. Svensson, and R. Christofferson. 2002. Importance of vascular endothelial growth factor A in the progression of experimental neuroblastoma. Angiogenesis 5:267-274.[CrossRef][Medline]
3. Bardos, J. I., N. M. Chau, and M. Ashcroft. 2004. Growth factor-mediated induction of HDM2 positively regulates hypoxia-inducible factor 1 expression. Mol. Cell. Biol. 24:2905-2914.
4. Baudino, T. A., C. McKay, H. Pendeville-Samain, J. A. Nilsson, K. H. Maclean, E. L. White, A. C. Davis, J. N. Ihle, and J. L. Cleveland. 2002. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 16:2530-2543.
5. Bergers, G., and L. E. Benjamin. 2003. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3:401-410.[CrossRef][Medline]
6. Brugarolas, J. B., F. Vazquez, A. Reddy, W. R. Sellers, and W. G. Kaelin, Jr. 2003. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4:147-158.[CrossRef][Medline]
7. Chappell, S. A., T. Walsh, R. A. Walker, and J. A. Shaw. 1997. Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor gene correlates with poor differentiation in early breast carcinomas. Br. J. Cancer 76:1558-1561.[Medline]
8. Chen, D., I. Livne-bar, J. L. Vanderluit, R. S. Slack, M. Agochiya, and R. Bremner. 2004. Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retinoblastoma. Cancer Cell 5:539-551.[CrossRef][Medline]
9. Eggert, A., N. Ikegaki, J. Kwiatkowski, H. Zhao, G. M. Brodeur, and B. P. Himelstein. 2000. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin. Cancer Res. 6:1900-1908.
10. Farah, M. H., J. M. Olson, H. B. Sucic, R. I. Hume, S. J. Tapscott, and D. L. Turner. 2000. Generation of neurons by transient expression of neural bHLH proteins in mammalian cells. Development 127:693-702.[Abstract]
11. Fernandez, P. C., S. R. Frank, L. Wang, M. Schroeder, S. Liu, J. Greene, A. Cocito, and B. Amati. 2003. Genomic targets of the human c-Myc protein. Genes Dev. 17:1115-1129.
12. Ferrara, N. 2002. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2:795-803.[CrossRef][Medline]
13. Fukuma, M., H. Okita, J. Hata, and A. Umezawa. 2003. Upregulation of Id2 an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma. Oncogene 22:1-9.[CrossRef][Medline]
14. Haggerty, T. J., K. I. Zeller, R. C. Osthus, D. R. Wonsey, and C. V. Dang. 2003. A strategy for identifying transcription factor binding sites reveals two classes of genomic c-Myc target sites. Proc. Natl. Acad. Sci. USA 100:5313-5318.
15. Hu, N., A. Gutsmann, D. C. Herbert, A. Bradley, W. H. Lee, and E. Y. Lee. 1994. Heterozygous Rb-1 delta 20/+ mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 9:1021-1027.[Medline]
16. Iakova, P., S. S. Awad, and N. A. Timchenko. 2003. Aging reduces proliferative capacities of liver by switching pathways of C/EBPalpha growth arrest. Cell 113:495-506.[CrossRef][Medline]
17. Iavarone, A., P. Garg, A. Lasorella, J. Hsu, and M. A. Israel. 1994. The helix-loop-helix protein Id-2 enhances cell proliferation and binds to the retinoblastoma protein. Genes Dev. 8:1270-1284.
18. Iavarone, A., E. R. King, X. M. Dai, G. Leone, E. R. Stanley, and A. Lasorella. 2004. Retinoblastoma promotes definitive erythropoiesis by repressing Id2 in fetal liver macrophages. Nature 432:1040-1045.[CrossRef][Medline]
19. Inoue, M., J. H. Hager, N. Ferrara, H. P. Gerber, and D. Hanahan. 2002. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1:193-202.[CrossRef][Medline]
20. Jacks, T., A. Fazeli, E. M. Schmitt, R. T. Bronson, M. A. Goodell, and R. A. Weinberg. 1992. Effects of an Rb mutation in the mouse. Nature 359:295-300.[CrossRef][Medline]
21. Jen, Y., K. Manova, and R. Benezra. 1997. Each member of the Id gene family exhibits a unique expression pattern in mouse gastrulation and neurogenesis. Dev. Dyn. 208:92-106.[CrossRef][Medline]
22. Jen, Y., K. Manova, and R. Benezra. 1996. Expression patterns of Id1, Id2, and Id3 are highly related but distinct from that of Id4 during mouse embryogenesis. Dev. Dyn. 207:235-252.[CrossRef][Medline]
23. Kim, E. S., A. Serur, J. Huang, C. A. Manley, K. W. McCrudden, J. S. Frischer, S. Z. Soffer, L. Ring, T. New, S. Zabski, J. S. Rudge, J. Holash, G. D. Yancopoulos, J. J. Kandel, and D. J. Yamashiro. 2002. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc. Natl. Acad. Sci. USA 99:11399-11404.
24. Lasorella, A., R. Boldrini, C. Dominici, A. Donfrancesco, Y. Yokota, A. Inserra, and A. Iavarone. 2002. Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma. Cancer Res. 62:301-306.
25. Lasorella, A., A. Iavarone, and M. A. Israel. 1996. Id2 specifically alters regulation of the cell cycle by tumor suppressor proteins. Mol. Cell. Biol. 16:2570-2578.[Abstract]
26. Lasorella, A., M. Noseda, M. Beyna, Y. Yokota, and A. Iavarone. 2000. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature 407:592-598.[CrossRef][Medline]
27. Lasorella, A., T. Uo, and A. Iavarone. 2001. Id proteins at the cross-road of development and cancer. Oncogene 20:8326-8333.[CrossRef][Medline]
28. Laughner, E., P. Taghavi, K. Chiles, P. C. Mahon, and G. L. Semenza. 2001. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21:3995-4004.
29. Lee, E. Y.-H. P., C.-Y. Chang, N. Hu, Y.-C. J. Wang, C.-C. Iai, K. Herrup, W.-H. Lee, and A. Bradley. 1992. Mice deficient for Rb are nonviable and show defects in neurogenesis and hematopoesis. Nature 359:288-294.[CrossRef][Medline]
30. Lentini, L., L. Pipitone, and A. Di Leonardo. 2002. Functional inactivation of pRB results in aneuploid mammalian cells after release from a mitotic block. Neoplasia 4:380-387.[CrossRef][Medline]
31. Liu, J., C. Lin, A. Gleiberman, K. A. Ohgi, T. Herman, H. P. Huang, M. J. Tsai, and M. G. Rosenfeld. 2001. Tbx19, a tissue-selective regulator of POMC gene expression. Proc. Natl. Acad. Sci. USA 98:8674-8679.
32. Lyden, D., K. Hattori, S. Dias, C. Costa, P. Blaikie, L. Butros, A. Chadburn, B. Heissig, W. Marks, L. Witte, Y. Wu, D. Hicklin, Z. Zhu, N. R. Hackett, R. G. Crystal, M. A. Moore, K. A. Hajjar, K. Manova, R. Benezra, and S. Rafii. 2001. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7:1194-1201.[CrossRef][Medline]
33. Lyden, D., A. Z. Young, D. Zagzag, W. Yan, W. Gerald, R. O'Reilly, B. L. Bader, R. O. Hynes, Y. Zhuang, K. Manova, and R. Benezra. 1999. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 401:670-677.[CrossRef][Medline]
34. Maandag, E. C., M. van der Valk, M. Vlaar, C. Feltkamp, J. O'Brien, M. van Roon, N. van der Lugt, A. Berns, and H. te Riele. 1994. Developmental rescue of an embryonic-lethal mutation in the retinoblastoma gene in chimeric mice. EMBO J. 13:4260-4268.[Medline]
35. Mori, S., S. I. Nishikawa, and Y. Yokota. 2000. Lactation defect in mice lacking the helix-loop-helix inhibitor Id2. EMBO J. 19:5772-5781.[CrossRef][Medline]
36. Moynahan, M. E., and M. Jasin. 1997. Loss of heterozygosity induced by a chromosomal double-strand break. Proc. Natl. Acad. Sci. USA 94:8988-8993.
37. Nikiforov, M. A., N. Popov, I. Kotenko, M. Henriksson, and M. D. Cole. 2003. The Mad and Myc basic domains are functionally equivalent. J. Biol. Chem. 278:11094-11099.
38. Nikitin, A., and W. H. Lee. 1996. Early loss of the retinoblastoma gene is associated with impaired growth inhibitory innervation during melanotroph carcinogenesis in Rb+/– mice. Genes Dev. 10:1870-1879.
39. Nishimori, H., Y. Sasaki, K. Yoshida, H. Irifune, H. Zembutsu, T. Tanaka, T. Aoyama, T. Hosaka, S. Kawaguchi, T. Wada, J. Hata, J. Toguchida, Y. Nakamura, and T. Tokino. 2002. The Id2 gene is a novel target of transcriptional activation by EWS-ETS fusion proteins in Ewing family tumors. Oncogene 21:8302-8309.[CrossRef][Medline]
40. Norton, J. D., R. W. Deed, G. Craggs, and F. Sablitzky. 1998. Id helix-loop-helix proteins in cell growth and differentiation. Trends Cell Biol. 8:58-65.[CrossRef][Medline]
41. Ochoa, A. L., N. A. Mitchner, C. D. Paynter, R. E. Morris, and N. Ben-Jonathan. 2000. Vascular endothelial growth factor in the rat pituitary: differential distribution and regulation by estrogen. J. Endocrinol. 165:483-492.[Abstract]
42. Pelengaris, S., M. Khan, and G. I. Evan. 2002. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109:321-334.[CrossRef][Medline]
43. Piao, Z., H. Kim, B. K. Jeon, W. J. Lee, and C. Park. 1997. Relationship between loss of heterozygosity of tumor suppressor genes and histologic differentiation in hepatocellular carcinoma. Cancer 80:865-872.[CrossRef][Medline]
44. Poulin, G., M. Lebel, M. Chamberland, F. W. Paradis, and J. Drouin. 2000. Specific protein-protein interaction between basic helix-loop-helix transcription factors and homeoproteins of the Pitx family. Mol. Cell. Biol. 20:4826-4837.
45. Poulin, G., B. Turgeon, and J. Drouin. 1997. NeuroD1/beta2 contributes to cell-specific transcription of the proopiomelanocortin gene. Mol. Cell. Biol. 17:6673-6682.[Abstract]
46. Raetz, E. A., M. K. Kim, P. Moos, M. Carlson, C. Bruggers, D. K. Hooper, L. Foot, T. Liu, R. Seeger, and W. L. Carroll. 2003. Identification of genes that are regulated transcriptionally by Myc in childhood tumors. Cancer 98:841-853.[CrossRef][Medline]
47. Ross, S. E., M. E. Greenberg, and C. D. Stiles. 2003. Basic helix-loop-helix factors in cortical development. Neuron 39:13-25.[CrossRef][Medline]
48. Russell, R. G., A. Lasorella, L. E. Dettin, and A. Iavarone. 2004. Id2 drives differentiation and suppresses tumor formation in the intestinal epithelium. Cancer Res. 64:7220-7225.
49. Ruzinova, M. B., and R. Benezra. 2003. Id proteins in development, cell cycle and cancer. Trends Cell Biol. 13:410-418.[CrossRef][Medline]
50. Ruzinova, M. B., R. A. Schoer, W. Gerald, J. E. Egan, P. P. Pandolfi, S. Rafii, K. Manova, V. Mittal, and R. Benezra. 2003. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 4:277-289.[CrossRef][Medline]
51. Scully, K. M., and M. G. Rosenfeld. 2002. Pituitary development: regulatory codes in mammalian organogenesis. Science 295:2231-2235.
52. Thiele, C. J., C. P. Reynolds, and M. A. Israel. 1985. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 313:404-406.[CrossRef][Medline]
53. Toma, J. G., H. El-Bizri, F. Barnabe-Heider, R. Aloyz, and F. D. Miller. 2000. Evidence that helix-loop-helix proteins collaborate with retinoblastoma tumor suppressor protein to regulate cortical neurogenesis. J. Neurosci. 20:7648-7656.
54. Treins, C., S. Giorgetti-Peraldi, J. Murdaca, G. L. Semenza, and E. Van Obberghen. 2002. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J. Biol. Chem. 277:27975-27981.
55. Trinh, E., E. L. Denchi, and K. Helin. 2004. Naturally death-resistant precursor cells revealed as the origin of retinoblastoma. Cancer Cell 5:513-515.[CrossRef][Medline]
56. Tsai, K. Y., D. MacPherson, D. A. Rubinson, A. Y. Nikitin, R. Bronson, K. L. Mercer, D. Crowley, and T. Jacks. 2002. ARF mutation accelerates pituitary tumor development in Rb+/– mice. Proc. Natl. Acad. Sci. USA 99:16865-16870.
57. Vandeputte, D. A., D. Troost, S. Leenstra, H. Ijlst-Keizers, M. Ramkema, D. A. Bosch, F. Baas, N. K. Das, and E. Aronica. 2002. Expression and distribution of id helix-loop-helix proteins in human astrocytic tumors. Glia 38:329-338.[CrossRef][Medline]
58. Viloria-Petit, A., L. Miquerol, J. L. Yu, M. Gertsenstein, C. Sheehan, L. May, J. Henkin, C. Lobe, A. Nagy, R. S. Kerbel, and J. Rak. 2003. Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. EMBO J. 22:4091-4102.[CrossRef][Medline]
59. Volpert, O. V., R. Pili, H. A. Sikder, T. Nelius, T. Zaichuk, C. Morris, C. B. Shiflett, M. K. Devlin, K. Conant, and R. M. Alani. 2002. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell 2:473-483.[CrossRef][Medline]
60. Vooijs, M., M. van der Valk, H. te Riele, and A. Berns. 1998. Flp-mediated tissue-specific inactivation of the retinoblastoma tumor suppressor gene in the mouse. Oncogene 17:1-12.[CrossRef][Medline]
61. Williams, B. O., E. M. Schmitt, L. Remington, R. T. Bronson, D. M. Albert, R. A. Weinberg, and T. Jacks. 1994. Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences. EMBO J. 13:4251-4259.[Medline]
62. Yancopoulos, G. D., S. Davis, N. W. Gale, J. S. Rudge, S. J. Wiegand, and J. Holash. 2000. Vascular-specific growth factors and blood vessel formation. Nature 407:242-248.[CrossRef][Medline]
63. Ying, Q. L., J. Nichols, I. Chambers, and A. Smith. 2003. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 115:281-292.[CrossRef][Medline]
64. Yokota, Y., A. Mansouri, S. Mori, S. Sugawara, S. Adachi, S. Nishikawa, and P. Gruss. 1999. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 397:702-706.[CrossRef][Medline]
65. Zheng, L., A. Flesken-Nikitin, P. L. Chen, and W. H. Lee. 2002. Deficiency of retinoblastoma gene in mouse embryonic stem cells leads to genetic instability. Cancer Res. 62:2498-2502.
66. Zundel, W., C. Schindler, D. Haas-Kogan, A. Koong, F. Kaper, E. Chen, A. R. Gottschalk, H. E. Ryan, R. S. Johnson, A. B. Jefferson, D. Stokoe, and A. J. Giaccia. 2000. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14:391-396.
This article has been cited by other articles:
| ||||||||||||
